Abstract: Oligosaccharide aromatic glycoside sulfates and physiologically acceptable salts thereof, are disclosed. Further, antiviral agents having these sulfate compounds as the active components, and particularly an antiviral agent, wherein the virus is one which causes AIDS (Acquired Immune Deficiency Syndrome), are disclosed. The active components or the glycoside sulfates, and the salts thereof, are characterized by an oligosaccharide aromatic glycoside sulfate in which the hydrogen of the position-1 hydroxyl group of the terminal sugar of an oligosaccharide is substituted with a specified formula having an alkyl group consisting of 1 to 18 carbons, an oxygen or no oxygen, and an allylene group. The number of constituent monosaccharides in the oligosaccharide portion is preferably within a range of 2 to 20. Further, 10% or more of the remaining hydroxyl groups of the sugar subunits are subjected to sulfated esterification.

Abstract: A sulfated oligoglycoside acylate comprising monosaccharides of a single or two kinds as the constituents, wherein the hydrogen in the hydroxyl group at the 1-position of a reducing end sugar of the oligosaccharide formed via the glycoside bond of these monosaccharides has been substituted with an aglycon selected from a group consisting of alkyl groups, aromatic alkyl groups, aromatic alkoxy groups and tocopheryl groups; from 12 to 80% of the residual hydroxyl groups have been acylated with an acyl group selected from a group consisting of aliphatic acyl groups and aromatic acyl groups; and 88 to 20% thereof have been sulfated; or a physiologically acceptable salt thereof provided that compounds wherein the aglycon is an alkyl group and the acyl group is an aliphatic acyl group are excluded is disclosed. Further, an antiviral agent, which exerts a long-lasting antiviral action particularly on HIV, containing said compound as an active ingredient is disclosed.

Abstract: A compound represented by formula (I): ##STR1## wherein R.sub.1 represents an alkyl group having from 1 to 18 carbon atoms; R.sub.2 represents an alkyl group having from 2 to 16 carbon atoms; rings A, B, C, and D each represents a 1,4-phenylene group or a 1,4-phenylene group having one or two halogen atoms; Y represents a single bond, ##STR2## m and n each represents 0 or 1; p represents 0, 1, or 2; q represents 0 or an integer of from 1 to 6; and C* and C** each represents an asymmetric carbon atom in an (S)- or (R)-configuration, and a liquid crystal composition containing the compound of formula (I). The compound of formula (I) is a chiral liquid crystal compound exhibiting large spontaneous polarization, a long helical pitch, an SC* phase in a broad temperature range including room temperature, satisfactory orientation, and a high rate of response.

Abstract: The present invention relates to novel tocopheryl oligosaccharides, acylated tocopheryl oligosaccharides, sulfated tocopheryl oligosaccharides, and antiviral agents including the sulfated tocopheryl oligosaccharides as active ingredients. In the tocopheryl oligosaccharide, the hydrogen atom of the hydroxy group at the 1-position in the terminal sugar moiety of an oligosaccharide which consists of 3.about.20 of identical or different repeating monosaccharide units selected from the group consisting of glucose, galactose, mannose, talose, idose, altrose, allose, glucose, xylose, arabinose, rhamnose, fucose, and fructose, which are glycoside-linked, is substituted by a tocopherol group. In the acylated tocopheryl oligosaccharides, each of any hydroxy group of the sugar moiety, other than the hydroxy group at the 1-position in the terminal sugar moiety of the oligosaccharide described above, is protected by an acyl group.

Abstract: An alkylated oligosaccharide and the acetyl derivative of the same, both useful as the raw material for producing lowly toxic surfactants or medicines. The alkylated oligosaccharide is prepared by substituting with an alkyl group having a linear or branched chain the hydrogen atom of the hydroxy group at the 1-position of a terminal sugar moiety of an oligosaccharide in which glucose moieties are .beta.(1.fwdarw.3)-glucoside-linked, or of an oligosaccharide in which galactose is .beta.(1.fwdarw.4)-glycoside-linked at the 4-position in the galactose moiety of lactose and in which galactose moieties are .beta.(1.fwdarw.4)-glycoside-linked in succession to the newly formed terminal galactose moieties. The invention also includes an acetyl derivative of the oligosaccharide, wherein the hydroxy groups excluding the 2-positional hydroxy group adjacent to the alkyl-ether-linking position in the terminal sugar moiety are acetylated, and a mixture thereof.

Abstract: A piperidine compound has the generic formula and is useful to treat arrhythmia. ##STR1## in which R1 is a lower alkyl and W is: ##STR2## X is --S--, --SO-- or --SO2--, R2 is hydrogen or --(CH2)n--Y, n is an integer of 1 to 5, Y is an aryl, pyridyl or a substituted pyridyl, X' is --CO-- or --CH(OH)--,p is an integer of 1 to 4, R12 is hydrogen or a lower alkyl, Y' is --(CH2)m--A, m is 1 or 2, A is an aryl, a substituted aryl, pyridyl or a substituted pyridyl, R12 and Y may form a 5- or 6-membered ring or a 5- or 6-membered ring having one or more substituents andR22 is hydrogen, a halogen, a lower alkyl, a lower alkoxy or hydroxy.

Abstract: A new piperidine compound is pharmacologically effective for treatment of the arrythmia and is defined by the formula: ##STR1## in which R.sup.1 is a lower alkyl or a tolyl, R.sup.2 is hydrogen, hydroxyl, a lower alkoxy or a lower alkyl, R.sup.3 is hydrogen, a lower alkyl, a lower alkenyl, a cycloalkyl or a cycloalkylalkyl, X is --CO--, --CH.sup.2 -- or --CHOH--, g is an integer of 1 to 3, h is an integer of 1 to 3, Y is hydrogen, a lower alkyl, a lower alkenyl, cyano, CH.sup.2 COOR, R being hydrogen or a lower alkyl, a cycloalkyl, a cycloalkylalkyl, ##STR2## 1 being 1 or 2, --A--B, A being --(CH.sub.2).sub.

Abstract: A piperidine compound has the generic formula and is useful to treat arrhythmia. ##STR1## in which R1 is a lower alkyl and W is: ##STR2## X is --S--, --SO-- or --SO2--, R2 is hydrogen or --(CH2)n--Y, n is an integer of 1 to 5, Y is an aryl, pyridyl or a substituted pyridyl, X' is --CO-- or --CH(OH)--,p is an integer of 1 to 4, R12 is hydrogen or a lower alkyl, Y' is --(CH2)m--A, m is 1 or 2, A is an aryl, a substituted aryl, pyridyl or a substituted pyridyl, R12 and Y may form a 5- or 6-membered ring or a 5- or 6-membered ring having one or more substituents andR22 is hydrogen, a halogen, a lower alkyl, a lower alkoxy or hydroxy.

Abstract: A 2,5-disubstituted pyrizine derivative and a 2,5-disubstituted pyrimidine derivative of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 each independently represents a straight-chain or branched alkyl group containing 1 to 20 carbon atoms;X represents a halogen atom; and ##STR2## represents a pyrazine-2,5-diyl or a pyrimidine-2,5-diyl group; each useful as an electrooptical display material are disclosed. Further a liquid crystal composition comprising said compounds as well as a ferroelectric display device wherein said liquid crystal composition is used are disclosed.

Abstract: A new piperidine compound is pharmacologically effective for treatment of arrythmia and has the formula: ##STR1## in which R.sup.1 is lower alkyl or tolyl; R.sup.2 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl or cycloalkylalkyl; X is --CO--, --CH.sub.2 -- or --CHOH--; the sum of g plus h equals the integer 3 or 4 with g and h being 1, 2 or 3; A is substituted or unsubstituted alkylene, alkenylene, --(CH.sub.2).sub.k --S--, wherein k is an integer of 2 to 5, or --(CH.sub.2).sub.p CO--, wherein p is an integer of 1 to 4; and B is a compound having at least one heterocyclic ring containing a nitrogen atom.

Abstract: A piperidine compound has the generic formula and is useful to treat arrhythmia. ##STR1## in which R1 is a lower alkyl and W is: ##STR2## X is --S--, --SO-- or --SO2--, R2 is hydrogen or --(CH2)n--Y, n is an integer of 1 to 5, Y is an aryl, pyridyl or a substituted pyridyl, X' is --CO-- or --CH(OH)--,p is an integer of 1 to 4, R12 is hydrogen or a lower alkyl, Y' is --(CH2)m--A, m is 1 or 2, A is an aryl, a substituted aryl, pyridyl or a substituted pyridyl, R12 and Y may form a 5- or 6-membered ring or a 5- or 6-membered ring having one or more substituents andR22 is hydrogen, a halogen, a lower alkyl, a lower alkoxy or hydroxy.

Abstract: An optically active lactone derivative represented by the following general formula (I): ##STR1## wherein R.sup.1 represents a straight-chain or branched alkyl, alkoxyl, alkanoyloxy, alkoxycarbonyl, alkoxyalkyl, alkoxyalkanoyloxy, or alkoxyalkoxyl group having 1 to 20 carbon atoms or an optically active group of each of the above kinds, R.sup.2 represents a straight-chain or branched alkyl group having 1 to 20 carbon atoms, ##STR2## or trans-1,4-cyclohexylene group of the formula and the asymmetric carbon atoms at the 2- and 4-positions in the lactone ring each independently is of the (S) or (R) configuration, an intermediate therefor, a process for producing the intermediate, a liquid-crystal composition, and a liquid-crystal display device.

Abstract: A 2,5-disubstituted pyrazine derivative and a 2,5-disubstituted pyrimidine derivative of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 each independently represents a straight-chain or branched alkyl group containing 1 to 20 carbon atoms;X represents a halogen atom; and ##STR2## represents a pyrazine-2,5-diyl or a pyrimidine-2,5-diyl group; each useful as an electrooptical display material are disclosed. Further a liquid crystal composition comprising said compounds as well as a ferroelectric display device wherein said liquid crystal composition is used are disclosed.

Abstract: A new piperidine compound is pharmacologically effective for treatment of the arrythmia and is defined by the formula: ##STR1## in which R.sup.1 is a lower alkyl or a tolyl, R.sup.2 is hydrogen, hydroxyl, a lower alkoxy or a lower alkyl, R.sup.3 is hydrogen, a lower alkyl, a lower alkenyl, a cycloalkyl or a cycloalkylalkyl, X is --CO--, --CH.sub.2 -- or --CHOH--, g is an integer of 1 to 3, h is an integer of 1 to 3, Y is hydrogen, a lower alkyl, a lower alkenyl, cyano, --CH.sub.2 COOR, R being hydrogen or a lower alkyl, a cycloalkyl, a cycloalkylalkyl, ##STR2## l being 1 or 2, --A--B, A being --(CH.sub.2).sub.

Abstract: A piperidine compound has the generic formula and is useful to treat arrhythmia. ##STR1## in which R.sup.1 is a lower alkyl and W is: ##STR2## X is --S--, --SO-- or --SO.sub.2 --, R.sup.2 is hydrogen or --(CH.sub.2).sub.n --Y, n is an integer of 1 to 5, Y is an aryl, pyridyl or a substituted pyridyl, X' is --CO-- or --CH(OH)--,p is an integer of 1 to 4, R.sup.12 is hydrogen or a lower alkyl, Y' is --(CH.sub.2).sub.m --A, m is 1 or 2, A is an aryl, a substituted aryl, pyridyl or a substituted pyridyl, R.sup.12 and Y may form a 5- or 6-membered ring or a 5- or 6-membered ring having one or more substituents andR.sup.22 is hydrogen, a halogen, a lower alkyl, a lower alkoxy or hydroxy.

Abstract: An optically active carboxylic acid derivative represented by the general formula ##STR1## wherein R represents a normal alkyl group having 1 to 20 carbon atoms, m and n represent 0 or 1 but are not 1 at the same time, X represents a hydrogen or halogen atom, Y represents a hydrogen or fluorine atom, provided that when Y is a hydrogen atom, X is a halogen atom, and that when n is 0, Y is ahydrogen atom, and Q* represents an optically active alkyl or 1-alkoxyethyl group having an asymmetric carbon atom.

Abstract: An optically active carboxylic acid derivative represented by the general formula ##STR1## wherein R represents a normal alkyl group having 1 to 20 carbon atoms, m and n represent 0 or 1 but are not 1 at the same time, X represents a hydrogen or halogen atom, Y represents a hydrogen or fluorine atom, provided that when Y is a hydrogen atom, X is a halogen atom, and that when n is 0, Y is a hydrogen atom, and Q* represents an optically active alkyl or 1-alkoxyethyl group having an asymmetric carbon atom.

Abstract: A new piperidine compound is pharmacologically effective for treatment of the arrythmia and is defined by the formula: ##STR1## in which R1 is a lower alkyl or a tolyl, R2 is hydrogen, hydroxyl, a lower alkoxy or a lower alkyl, R3 is hydrogen, a lower alkyl, a lower alkenyl, a cycloalkyl or a cycloalkylalkyl, X is --CO--, --CH2-- or --CHOH--, g is an integer of 1 to 3, h is an integer of 1 to 3, Y is hydrogen, a lower alkyl, a lower alkenyl, cyano, --CH2COOR, R being hydrogen or a lower alkyl, a cycloalkyl, a cycloalkylalkyl, ##STR2## 1 being 1 or 2, --A--B, A being --(CH2)n--, n being an integer of 1 to 5, a straight-chain alkylene group having 1 to 5 carbon atoms which is a divalent group derived from a straight-chain alkane having lower alkyl, phenyl or hydroxyl group(s) bonded directly to one or more carbon atoms constituting said alkane by removing a hydrogen atom bonded to each of the carbon atoms placed at both ends thereof,a straight-chain alkylene group having 1 to 5 carbon atoms which is a divalent

Abstract: A lith-type silver halide photographic material comprising a tetrahydro-1,3,5-triazine-2-thione derivative and a polyalkylene oxide derivative.

Abstract: Derivatives of theophylline substituted at the 7 position with various substituents containing a homopiperazine nucleus. The compounds can be prepared reacting theophylline or reactive intermediate containing same with a homopiperazine compound. The compounds exhibit antihistaminic activity and vasodilating activity.